DT-Real Study: Real-World Outcomes of Durvalumab With or Without Tremelimumab in Advanced HCC - OncoDaily Real-World Outcomes of Durvalumab With or Without Tremelimumab in Advanced HCC of DT-Real Study.

DT-Real Study: Real-World Outcomes of Durvalumab With or Without Tremelimumab in Advanced HCC

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Durvalumab #Tremelimumab #HCC

#RAMPART demonstrated improved disease free suvivival at three years in resectable Renal Cell Carcinoma with addition of adjuvant #Durvalumab and #Tremelimumab

3year DFS 81% vs 73% for surveillance

Nb increased tox, including myocarditis

#ESMO25 @oncoalert.bsky.social

NICE backs AstraZeneca’s dual immunotherapy for advanced liver cancer - PharmaTimes Imfinzi and Imjudo combination recommended as first-line treatment

#oncology #NICE #AstraZeneca #dualimmunotherapy #advancedlivercancer #livercancer #Imfinzi #durvalumab #Imjudo #tremelimumab #Advancedhepatocellularcarcinoma #unresectablehepatocellularcarcinoma #HCC #NICEapproval #STRIDEregimen #primarylivercancer #BritishLiverTrust
zurl.co/M3ftp

ROWAN Study of TheraSphere with Durvalumab and Tremelimumab in HCC Completed Enrollment - OncoDaily Rowan Study with Durvalumab and Tremelimumab and Therasphere in HCC completed enrollment

ROWAN Study of TheraSphere with Durvalumab and Tremelimumab in HCC Completed Enrollment

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ROWAN #TheraSphere #Durvalumab #Tremelimumab #HCC

@ILCAnews Dr. Meyer @ucl cites some examples of “markers” of #HCC response to systemic rx or lacktherof
⬆️AFP and #ramucirumab in 2L
#HCV pos and #sorafenib (maybe)
#NAFLD and potential resistance to ICIs @CancerInflam
Non viral hepatitis and #durvalumab #tremelimumab #ilca22

@ILCAnews Drs. Tim Meyer @ucl and Katie Kelley @UCSFMedicine review the current state of #HCC systemic therapy #sorafenib #lenvatinib #cabozantinib #pembrolizumab #atezolizumab #bevacizumab #durvalumab #tremelimumab #camrelizumab #tislelizumab #rivoceranib #ilca22

#Tremelimumab plus #Durvalumab in Unresectable Hepatocellular Carcinoma | NEJM Evidence #hcctwitter evidence.nejm.org/doi/full/10.1056/EVIDoa2...

Durvalumab Plus Tremelimumab Improves OS in Unresectable HCC The combination of durvalumab and tremelimumab demonstrat...

#Durvalumab Plus #Tremelimumab Improves OS in Unresectable #HCC . Commentary by ⁦@GABOUALFA⁩ highlighting study findings www.onclive.com/view/durvalumab-plus-tre...